JP2016531850A - 頭痛治療用の鼻腔内ｄｈｅ - Google Patents

頭痛治療用の鼻腔内ｄｈｅ Download PDF

Info

Publication number
JP2016531850A
JP2016531850A JP2016516520A JP2016516520A JP2016531850A JP 2016531850 A JP2016531850 A JP 2016531850A JP 2016516520 A JP2016516520 A JP 2016516520A JP 2016516520 A JP2016516520 A JP 2016516520A JP 2016531850 A JP2016531850 A JP 2016531850A
Authority
JP
Japan
Prior art keywords
dhe
powder formulation
administered
auc
minutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016516520A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016531850A5 (enExample
Inventor
俊志 治田
俊志 治田
ニキレシュ エヌ． シン
ニキレシュ エヌ． シン
ジョン コリンズ
ジョン コリンズ
サルバドール リコ
サルバドール リコ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shin Nippon Biomedical Laboratories Ltd
Original Assignee
Shin Nippon Biomedical Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shin Nippon Biomedical Laboratories Ltd filed Critical Shin Nippon Biomedical Laboratories Ltd
Publication of JP2016531850A publication Critical patent/JP2016531850A/ja
Publication of JP2016531850A5 publication Critical patent/JP2016531850A5/ja
Priority to JP2019162995A priority Critical patent/JP6902583B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016516520A 2013-09-24 2014-09-24 頭痛治療用の鼻腔内ｄｈｅ Pending JP2016531850A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019162995A JP6902583B2 (ja) 2013-09-24 2019-09-06 頭痛治療用の鼻腔内ｄｈｅ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361881947P 2013-09-24 2013-09-24
US61/881,947 2013-09-24
PCT/IB2014/002706 WO2015044782A2 (en) 2013-09-24 2014-09-24 Intranasal dhe for the treatment of headache

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019162995A Division JP6902583B2 (ja) 2013-09-24 2019-09-06 頭痛治療用の鼻腔内ｄｈｅ

Publications (2)

Publication Number Publication Date
JP2016531850A true JP2016531850A (ja) 2016-10-13
JP2016531850A5 JP2016531850A5 (enExample) 2017-10-26

Family

ID=52424045

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016516520A Pending JP2016531850A (ja) 2013-09-24 2014-09-24 頭痛治療用の鼻腔内ｄｈｅ
JP2019162995A Active JP6902583B2 (ja) 2013-09-24 2019-09-06 頭痛治療用の鼻腔内ｄｈｅ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019162995A Active JP6902583B2 (ja) 2013-09-24 2019-09-06 頭痛治療用の鼻腔内ｄｈｅ

Country Status (6)

Country Link
US (5) US20160228433A1 (enExample)
EP (2) EP3049059B1 (enExample)
JP (2) JP2016531850A (enExample)
DK (1) DK3049059T3 (enExample)
ES (1) ES2904570T3 (enExample)
WO (1) WO2015044782A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101980738A (zh) 2008-02-07 2011-02-23 华盛顿大学 圆周气雾设备
EP2680913B1 (en) 2011-03-03 2020-05-06 Impel NeuroPharma Inc. Nasal drug delivery device
CN107376071B (zh) 2011-05-09 2021-07-09 英倍尔药业股份有限公司 用于将化合物递送到使用者的上部嗅觉区的喷嘴
HK1222358A1 (zh) 2013-04-28 2017-06-30 Impel Neuropharma Inc. 医用单位剂量容器
EP3049059B1 (en) 2013-09-24 2021-11-03 Satsuma Pharmaceuticals, Inc. Intranasal dhe formulation for the treatment of headache
EP3341059B1 (en) 2015-09-10 2022-03-02 Impel NeuroPharma Inc. In-line nasal delivery device
CA3030359A1 (en) 2016-08-05 2018-02-08 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical powder compositions
BR112019027508A2 (pt) * 2017-07-02 2020-07-07 Dr. Reddys Laboratories Limited formas de dosagem nasal de di-hidroergotamina
US11571532B2 (en) 2017-11-21 2023-02-07 Impel Pharmaceuticals Inc. Intranasal device with dip tube
US11395887B2 (en) 2017-11-21 2022-07-26 Impel Pharmaceuticals Inc. Intranasal device with inlet interface
EP3735223A4 (en) 2018-01-05 2021-10-13 Impel Neuropharma Inc. INTRANASAL ADMINISTRATION OF OLANZAPINE BY A PRECISION OLFACTORY DEVICE
BR112020013744A8 (pt) * 2018-01-05 2022-10-18 Impel Neuropharma Inc Dispensação intranasal de di-hidroergotamina por dispositivo olfativo de precisão
JP2021532098A (ja) 2018-07-19 2021-11-25 インペル ニューロファーマ インコーポレイテッド パーキンソン病の治療のためのレボドパおよびドーパデカルボキシラーゼ阻害剤の呼吸管路送達
CA3122396A1 (en) 2018-12-11 2020-06-18 Satsuma Pharmaceuticals, Inc. Compositions, devices, and methods for treating or preventing headaches
CN113473967B (zh) 2019-01-03 2022-09-09 英倍尔制药公司 经鼻药物递送装置
AU2020277313A1 (en) 2019-05-17 2022-01-20 Impel Pharmaceuticals Inc. Single-use nasal delivery device
IL324950A (en) * 2023-05-31 2026-01-01 Shin Nippon Biomedical Laboratories Ltd Compositions for enhanced mucosal penetration

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1059841A (ja) * 1996-02-27 1998-03-03 Teijin Ltd 吸収性が改善された粉末状経鼻投与組成物
JP2003206227A (ja) * 2002-01-09 2003-07-22 Ｔｒａｎｓｌａｔｉｏｎａｌ Ｒｅｓｅａｒｃｈ株式会社 薬物の経鼻投与用組成物
JP2005520799A (ja) * 2001-12-27 2005-07-14 ベザン アンテルナシオナル ベルジック 即時放出型の微細化された医薬または栄養補助食品の粉末
WO2006016530A1 (ja) * 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
JP2006519219A (ja) * 2003-02-28 2006-08-24 ブリタニア ファーマシューティカルズ リミテッド 鼻腔送達用医薬品組成物
US20110171141A1 (en) * 2009-06-26 2011-07-14 Kellerman Donald J Administration of dihydroergotamine mesylate particles using a metered dose inhaler
JP2013126989A (ja) * 2010-04-15 2013-06-27 Shin Nippon Biomedical Laboratories Ltd 鼻内送達のための方法および組成物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2750090A1 (de) 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
US5169849A (en) * 1982-02-01 1992-12-08 Sandoz Ltd. Nasal pharmaceutical compositions
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
DE69434304T2 (de) * 1993-03-26 2005-12-29 Merkus, Franciscus Wilhelmus H.M. Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin
SE9803770D0 (sv) 1998-11-05 1998-11-05 Astra Ab Dry powder pharmaceutical formulation
AU7685200A (en) * 1999-10-12 2001-04-23 Kaken Pharmaceutical Co., Ltd. Powdery inhalational preparations and process for producing the same
EP1397173A1 (en) * 2001-06-20 2004-03-17 Nektar Therapeutics Powder aerosolization apparatus and method
MXPA03005980A (es) * 2001-07-05 2003-09-10 Translational Res Ltd Composiciones para administracion nasal de insulina.
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
GB0228826D0 (en) * 2002-12-11 2003-01-15 Okpala Joseph Hair technology in creating particles with improved delivery capabilities
US7638138B2 (en) * 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
EP1663159A4 (en) 2003-09-10 2010-06-09 Map Pharmaceuticals Inc AEROSOL FORMULATIONS FOR THE DELIVERY OF DIHYDROERGOTAMINE TO THE SYSTEMIC CIRCULATION BY PULMONARY INHALATION
JP5694643B2 (ja) * 2005-08-05 2015-04-01 スリーエム イノベイティブ プロパティズ カンパニー 改善された流動性を示す組成物
WO2007066646A1 (ja) * 2005-12-06 2007-06-14 Asahi Kasei Chemicals Corporation 高速直接打錠による錠剤の製造方法
ES2652415T3 (es) * 2006-12-26 2018-02-02 Shin Nippon Biomedical Laboratories, Ltd. Preparación para aplicación transnasal
PL2425820T3 (pl) 2007-02-11 2015-08-31 Map Pharmaceuticals Inc Sposób terapeutycznego stosowania dhe w celu umożliwienia szybkiego złagodzenia migreny przy jednoczesnym zminimalizowaniu profilu działań niepożądanych
JP2009076785A (ja) * 2007-09-21 2009-04-09 Panasonic Corp 半導体装置の製造方法
US20110082150A1 (en) 2008-02-11 2011-04-07 Robert Owen Cook Headache pre-emption by dihydroergotamine treatment during headache Precursor events
US9101539B2 (en) * 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
US8827946B2 (en) 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
SG181896A1 (en) 2009-12-23 2012-07-30 Map Pharmaceuticals Inc Novel ergoline analogs
WO2011163600A2 (en) * 2010-06-25 2011-12-29 Apt Pharmaceuticals, Inc. Tacrolimus compositions for aerosol administration
ES2659761T3 (es) 2011-01-31 2018-03-19 Shin Nippon Biomedical Laboratories, Ltd. Dispositivos de administración intranasal
EP2680913B1 (en) 2011-03-03 2020-05-06 Impel NeuroPharma Inc. Nasal drug delivery device
EP2787970B1 (en) * 2011-12-11 2018-04-11 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
US20140179705A1 (en) 2012-12-21 2014-06-26 Map Pharmaceuticals, Inc. 8'-hydroxy-dihydroergotamine compounds and compositions
EP2935280A4 (en) 2012-12-21 2016-05-25 Map Pharmaceuticals Inc 8'-HYDROXY-DIHYDROERGOTAMINE COMPOUNDS AND COMPOSITIONS
EP3049059B1 (en) 2013-09-24 2021-11-03 Satsuma Pharmaceuticals, Inc. Intranasal dhe formulation for the treatment of headache
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
CA3030359A1 (en) 2016-08-05 2018-02-08 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical powder compositions
JP7523879B2 (ja) 2016-10-31 2024-07-29 エスエス製薬株式会社 医薬組成物
BR112019027508A2 (pt) 2017-07-02 2020-07-07 Dr. Reddys Laboratories Limited formas de dosagem nasal de di-hidroergotamina
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
BR112020013744A8 (pt) 2018-01-05 2022-10-18 Impel Neuropharma Inc Dispensação intranasal de di-hidroergotamina por dispositivo olfativo de precisão
CA3122396A1 (en) 2018-12-11 2020-06-18 Satsuma Pharmaceuticals, Inc. Compositions, devices, and methods for treating or preventing headaches

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1059841A (ja) * 1996-02-27 1998-03-03 Teijin Ltd 吸収性が改善された粉末状経鼻投与組成物
JP2005520799A (ja) * 2001-12-27 2005-07-14 ベザン アンテルナシオナル ベルジック 即時放出型の微細化された医薬または栄養補助食品の粉末
JP2003206227A (ja) * 2002-01-09 2003-07-22 Ｔｒａｎｓｌａｔｉｏｎａｌ Ｒｅｓｅａｒｃｈ株式会社 薬物の経鼻投与用組成物
JP2006519219A (ja) * 2003-02-28 2006-08-24 ブリタニア ファーマシューティカルズ リミテッド 鼻腔送達用医薬品組成物
WO2006016530A1 (ja) * 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
US20110171141A1 (en) * 2009-06-26 2011-07-14 Kellerman Donald J Administration of dihydroergotamine mesylate particles using a metered dose inhaler
JP2013126989A (ja) * 2010-04-15 2013-06-27 Shin Nippon Biomedical Laboratories Ltd 鼻内送達のための方法および組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J PHARM SCI, vol. 86 (7), JPN6018019060, 1997, pages 802 - 807, ISSN: 0004029790 *

Also Published As

Publication number Publication date
US20230000860A1 (en) 2023-01-05
JP6902583B2 (ja) 2021-07-14
US20240108619A1 (en) 2024-04-04
EP4008307A1 (en) 2022-06-08
JP2020007342A (ja) 2020-01-16
US20200179379A1 (en) 2020-06-11
US20160228433A1 (en) 2016-08-11
WO2015044782A2 (en) 2015-04-02
WO2015044782A3 (en) 2015-06-11
ES2904570T3 (es) 2022-04-05
US12594273B2 (en) 2026-04-07
DK3049059T3 (da) 2022-01-31
EP3049059A2 (en) 2016-08-03
EP3049059B1 (en) 2021-11-03
US20190275036A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
JP6902583B2 (ja) 頭痛治療用の鼻腔内ｄｈｅ
US12109196B2 (en) Non-sedating dexmedetomidine treatment regimens
JP5886632B2 (ja) オキシコドンおよびナロキソンを含む即時放出医薬組成物
AU2017312660A1 (en) Methods of treating eosinophilic esophagitis
US20200345730A1 (en) Compositions, Devices, and Methods for Treating or Preventing Headaches
CN109069416A (zh) 缓释丁丙诺啡微球(srbm)及其使用方法
AU2011253775B2 (en) Compositions and Methods for Increasing Blood Platelet Levels in Humans
JP2022514340A (ja) 過剰摂取および報酬に基づく障害を処置するための、組成物、装置、および方法
HK40076888A (en) Intranasal dhe formulation for the treatment of headache
CN116801863A (zh) 右美托咪定治疗方案
HK1233158B (en) Intranasal dhe formulation for the treatment of headache
HK1170673B (en) Compositions and methods for increasing blood platelet levels in humans

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170914

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190509